Advancing Collective Priorities: A Canadian Carer Strategy

The Canadian Cancer Action Network, in partnership with Carers Canada and the Canadian Home Care Association, is pleased to publically launch the 2017 report, Advancing Collective Priorities: A Canadian Carer Strategy today. Over 8 million carers (also referred to as family caregivers) impact the lives of Canadians every day. Providing care and support to loved

New Drug Therapy – COTELLIC ZELBORAF Effective June 1, 2017

New criteria for the following products have been added to the Newfoundland and Labrador Prescription Drug Program (NLPDP) Benefit List effective June 1, 2017. Special Authorization New Addition The following was reviewed by the pan Canadian Oncology Drug Review (pCODR) recommended for coverage with criteria: COTELLIC (Cobimetinib) 20mg DIN 02452340 In combination with vemurafenib, for

Ontario Cancer Research Ethics Board Call for Community Members

A research ethics board (REB) is a body of researchers, community members and others that is established to review the ethical acceptability of research involving humans. Working within a defined regulatory and ethical framework, the REB’s role is to safeguard the rights and welfare of the individuals who volunteer to participate in research. The composition

Provincial/Territorial Premiers Prescription for Health Encouraging; Patient groups look forward to working with them to achieve equitable access to treatments for all Canadians

EDMONTON, AB. – July 19th, 2017 – The provincial/territorial Premiers met today at the Council of the Federation in Edmonton, Alberta. Health was on the agenda. Patient groups, patients, caregivers and their supporters were in Edmonton to follow the outcome of the meeting. They wanted to ensure that the decisions made enhanced access to necessary

Cotellic (Cobimetinib) in Québec

COBIMETINIB: in association with vemurafenib, for first-line or second-line treatment following a failure with cytotoxic chemotherapy or with immunotherapy targeting the PD-1 or the CTLA-4, of an unresectable or metastatic melanoma with a BRAF V600 mutation, in persons whose ECOG performance status is 0 or 1. The initial authorization is for a maximum duration of

Do you have a bright idea to change cancer care?

Entering its second year, the Astellas Oncology C3 Prize® is once again calling for applicants from all over the world and from all backgrounds to submit their ideas for innovations to change cancer care. The C3 Prize, which aims to inspire and foster innovative, non-medical, non-treatment ideas, is offering $100,000 in unrestricted grants and access

PMPRB – Recommendations on Proposed Amendments to the Patented Medicines Regulations

In May 2017, Health Canada announced proposed amendments to the Patented Medicines Regulations. The amendments would enable the Patented Medicines Prices Review Board to better protect Canadians from paying excessive prices for patented drugs. The regulations have not been changed in over 20 years, despite major changes in the pharmaceutical market. Canadians are now paying

Online Tool to Help Breast Cancer Patients

On June 8th, Be The Choice launched a new, online tool that will help breast cancer patients and their loved ones navigate different treatment options. Following a diagnosis, patients can access the fully bilingual decision tree to easily move through a series of treatment pathways and decision points. Key Facts: The decision tree was designed